STRATA Skin Sciences to Participate in the MicroCap Rodeo Best Ideas Bowl
HORSHAM, PA / ACCESSWIRE / October 6, 2020 / STRATA Skin Sciences (NASDAQ:SSKN) ("STRATA") a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced that Dr. Dolev Rafaeli, STRATA's Chief Executive Officer, will present a corporate overview at the MicroCap Rodeo Best Ideas Bowl, which is being held virtually on October 13th - 16th, 2020.
STRATA Skin Sciences, Inc. is scheduled to present on Tuesday, October 13th at 2:00 pm Eastern Time, with one-on-one meetings to be held throughout the conference. The presentation will be webcast live and available for replay at: www.strataskinsciences.com.
To receive additional information, request an invitation or to schedule a one-on-one meeting, please email email@example.com.
About the MicroCap Rodeo Best Ideas Bowl
The MicroCap Rodeo is back with its first ever "Best Ideas Bowl." This conference is a virtual conference that brings you the top 25 best ideas from the buy side. Qualified institutional investors recommended each of the 25 companies represented as one of their best ideas. Those of you who attended the 2019 MicroCap Rodeo in Austin, Texas, know that we're focused on alpha. The Best Ideas Bowl is sure to have some big winners too.
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions. Its products include the XTRAC® excimer laser and VTRAC® lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions; and the STRATAPEN® MicroSystem, marketed specifically for the intended use of micropigmentation.
The Company's proprietary XTRAC® excimer laser delivers a highly targeted therapeutic beam of UVB light to treat psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma, diseases, which impact over 35 million patients in the United States alone. The technology is covered by multiple patents, including exclusive rights for patents for the delivery of treatments to vitiligo patients.
STRATA's unique business model leverages targeted Direct to Consumer (DTC) advertising to generate awareness and utilizes its in-house call center and insurance advocacy teams to increase volume for the Company's partner dermatology clinics.
The XTRAC® business has used this proven DTC model to grow its domestic dermatology partner network to over 789 clinics, with a worldwide installed base of over 2,000 devices. The Company is able to offer 90% of DTC patients an introduction to physicians prescribing a reimbursable solution, using XTRAC®, within a 10 mile radius of their house. The Company is a leader in dermatology in-clinic business generation for its partners.
Matthew Hill, Chief Financial Officer
STRATA Skin Sciences, Inc.
SOURCE: STRATA Skin Sciences